Table 1 Cases of immunotherapy induced sarcoid and sarcoid-like granulomatous reaction in metastatic melanoma
Age*, Sex | Stage | Immunotherapy (cycle prior to sarcoid diagnosis) | Melanoma Response | Sarcoid Organ Involvement | Symptoms related to Sarcoid | Sarcoid Treatment Required | Reference |
|---|---|---|---|---|---|---|---|
67 F | IV | Ipilimumab (4+) | stable disease | lung, mediastinum, skin | dyspnea | unknown | [5] |
62 F | IV | Ipilimumab (not reported) | stable disease | mediastinal LN, skin, bronchus | none | No | [6] |
49 M | IV | Ipilimumab (4) | complete response | mediastinal/hilar LN | none | N0 | [7] |
48 F | IV | Ipilimumab (2) | progression | Widespread LN, lung, spleen | dyspnea, cough, fatigue | Yes - steroids | [8] |
63 M | IV | Ipilimumab (4) | progression | lung | dyspnea, dry cough, hypoxia | Yes-steroids | [9] |
57 M | IIIB | Ipilimumab (6) | Unknown | lung, hilar LN, skin | none | No | [10] |
55 M | IIIB | Ipilimumab (2) | progression | lung, mediastinal/hilar LN, skin | dyspnea, hypoxia | Yes-steroids | [11] |
37 M | IV | Ipilimumab (4) | stable disease | mediastinal/hilar LN, brain | fatigue, arthralgia, anorexia, weight loss, headache | Yes-steroids | [12] |
44 M | IV | Ipilimumab (4) | partial response | spleen | none | No | [13] |
57 M | IV | Nivolumab (not reported) | complete response | mediastinal/hilar LN, skin | none | No | [14] |